Kiniksa Pharmaceuticals International (KNSA) Depreciation and Depletion (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Depreciation and Depletion of $144000.0 for Q1 2026, up 19.01% on a QoQ basis from $121000.0 in Q4 2025, and up 311.43% year-over-year from $35000.0 in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Depreciation and Depletion (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Depreciation and Depletion history runs 10 years deep, the most recent figure standing at $144000.0 for Q1 2026.
- Quarterly Depreciation and Depletion rose 311.43% year-over-year to $144000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $305000.0 (down 7.29% YoY) and the FY2025 annual result came in at $196000.0, down 56.25% from the prior year.
- Depreciation and Depletion was $144000.0 for Q1 2026 at Kiniksa Pharmaceuticals International, up from $121000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $359000.0 in Q1 2022 and bottomed at $13000.0 in Q2 2025.
- A 5-year average of $181000.0 and a median of $154000.0 in 2024 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2025 — Depreciation and Depletion sank 89.08% — and 2026, when it soared 311.43%.
- Kiniksa Pharmaceuticals International's Depreciation and Depletion stood at $294000.0 in 2022, then fell by 19.73% to $236000.0 in 2023, then sank by 62.71% to $88000.0 in 2024, then soared by 37.5% to $121000.0 in 2025, then rose by 19.01% to $144000.0 in 2026.
- Business Quant data shows KNSA's Depreciation and Depletion at $144000.0 in Q1 2026, $121000.0 in Q4 2025, and $27000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 36.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 28.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | 144,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 144,000.00 |
| Mar 31, 2026 | 144,000.00 |
| Dec 31, 2025 | 121,000.00 |
| Dec 31, 2025 | 121,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 88,000.00 |
| Dec 31, 2024 | 88,000.00 |
| Sep 30, 2024 | 87,000.00 |
| Sep 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 119,000.00 |
| Jun 30, 2024 | 119,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Dec 31, 2023 | 236,000.00 |
| Dec 31, 2023 | 236,000.00 |